Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Immunovant Sector: Pharmaceuticals and biotechnology (autoimmune and immunology therapeutics) HQ: 320 W 37th St., New York, NY Year Founded: 2018 Key Leaders: Eric Venker, MD, PharmD, CEO Number of Employees: 362 Stage: Public Financial Snapshot: $3.83 billion Notable Investors: SG Americas Securities, Roivant Sciences, RTW Investments, and BVF Partners Key Products: Immunovant is developing Batoclimab, an FcRn-targeting monoclonal antibody for autoimmune diseases (MG, TED, Graves disease), which is in Phase 3 registrational trials
Use within 28 days
In fact, our bodies are designed to do just that to prevent starvation and pool resources to sustain life
Injection training: patients receive hands-on training on subcutaneous self-injection technique, vial storage (refrigerated), and reconstitution if supplied lyophilized
US$ 25.53
US$ 22.38
US$ 24.98
US$ 23.02
US$ 20.59
US$ 28.14
US$ 24.87
US$ 23.13
US$ 28.73
US$ 22.00
US$ 27.92
US$ 27.39
US$ 20.21
US$ 21.06
